TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections

The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.

TD-1792 is compared to vancomycin for the treatment of cSSSI.

Inclusion Criteria:

• major abscess requiring surgical incision and drainage,infected burn, deep/extensive cellulitis, infected ulcer, wound infections
• requires at least 7 days of intravenous antibiotic treatment

Exclusion Criteria:

• more than 24 hours of antibiotic therapy
• moderate or severe liver disease
• severely neutropenic
• baseline QTc > 500 msec, congenital long QT syndrome, uncompensated heart failure, uncorrected abnormal K+ or Mg++ blood levels or severe left ventricular hypertrophy